KẾT QUẢ SỬ DỤNG SURFACTANT LIỀU CAO TRONG ĐIỀU TRỊ HỘI CHỨNG SUY HÔ HẤP CẤP Ở TRẺ ĐẺ NON TẠI BỆNH VIỆN NHI TRUNG ƯƠNG

Abstract

Evaluation of the results of using high-dose surfactant (alfa poractant) in the treatment of acute respiratory distress syndrome in premature infants at the National Children's Hospital from January 2020 to December 2022 In a cross-sectional descriptive study, we had 133 premature infants using surfactant (alfa poractant) at a dose of 100 - 200 mg/kg. Results: 45 children received low dose (33.8%) and 88 children received high dose (66.2%). There were no differences between the two groups in terms of birth weight, prenatal corticosteroid use, sex ,time of first use alfa poractant. The high-dose group had less reuse, fewer early complications, fewer early deaths (≤72 h) and more radiographic changes ≥2 at 6 hours than the low-dose group with p<0.05. The evolution of oxygen index, ventilator parameters, blood gas significantly improved after 6 hours of use in the high dose group from the beginning. Conclusions: High dose surfactant reduced ventilator parameters, reduced oxygen demand, improved blood gases, and reduced complications and premature death better than low dose.